Breaking News

How obesity drugs are impacting devices, Fauci’s new gig, & what happens when helpline volunteers are replaced by a chatbot

June 27, 2023
Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in for Liz. Today's lineup is jam-packed with stellar STAT stories to help you kick-start your Tuesday.

The obesity revolution

The rise of effective obesity drugs raises new opportunities — and challenges — for device makers

A collage illustration with a patient in the center with a hand to the left administering treatment and a doctor in the background.Katy Lemay for STAT

A new class of weight loss drugs isn't just changing how doctors and patients think about obesity, it's shaking up the medical device world, where companies have for years been working on new surgical tools that shrink a person's stomach or take up space within it. But with medicines that can reduce a person's weight by 15% and newer, experimental drugs that could be even more effective (see below), demand for certain devices could drop. 

"A device that may give you 15% weight loss, and looked like it was blowing away the competition, is now going to look weak in comparison to drugs," Lee Kaplan, director of Massachusetts General Hospital's obesity institute, told STAT's Lizzy Lawrence. Still, device makers see opportunity in the surge of interest in treating obesity, and some companies are pitching that their products could be used alongside these new drugs. Read more.


Obesity

Lilly's 'triple-G' drug shows biggest weight loss yet in trial

Eli Lilly yesterday reported the most dramatic weight loss yet for an obesity drug, with patients losing 24.2% of their body weight in a mid-stage clinical trial. Researchers also found that the drug, dubbed retratutide, significantly reduced liver fat, which is associated with nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments. 

If the results for retatrutide hold up in a follow-on study, Lilly could catapult into the lead in the race to develop more effective weight loss drugs, writes STAT's Elaine Chen, reporting from the American Diabetes Association meeting in San Diego. Unlike Ozempic and Wegovy, weight loss drugs marketed by Novo Nordisk, or Lilly's Mounjaro, retatrutide targets three different hormones — GLP-1, GIP, and glucagon — earning it the "triple G" drug moniker.


cancer

A multi-cancer screening test faces rocky road to Medicare reimbursement

Bay Area cancer detection firm Grail has high hopes for Galleri, a blood-based test that can detect early signs of 50 different cancers from a person's blood before they show symptoms. But the test is for now a niche product. It's not approved by the FDA, it costs $950, and, importantly, it isn't covered by Medicare. The company has been lobbying for that to change, but its path to reimbursement won't be easy, STAT's John Wilkerson tells us. 

Medicare generally currently doesn't cover tests that screen healthy people, with limited exceptions. The projected costs from widely using this test could be huge, and there are still open questions around whether detecting cancer early would truly translate into better outcomes for patients and the health care system at large, which is an argument that Grail and other cancer detection companies have repeatedly made. Read more.



Closer Look

Volunteers left adrift after an eating disorder helpline turns to chatbots

Dozens of volunteers working a helpline run by the National Eating Disorders Association recently received a surprise announcement: Their services were no longer needed. Instead, the helpline would rely on an AI chatbot called Tessa to reduce ballooning wait times. But that strategy change has consequences for the recently replaced volunteers, writes STAT's Mohana Ravindranath, many of whom have struggled with eating disorders and who said that working the helpline sparked an interest in going to graduate school to pursue a career as a therapist.

There's also intrinsic value in callers being able to connect with another human being, one former volunteer told Ravindranath, especially since many people call amid mental health crises. "A robot has not experienced the human experience," she said. "We can at least relate on some level, or at least be able to put ourselves in someone else's shoes and see where they've come from." Read more.


infectious disease

Anthony Fauci, top infectious disease expert, heads to academia

After nearly 40 years spent running the National Institute of Allergy and Infectious Diseases at the NIH, Anthony Fauci, widely regarded as the top infectious disease expert in the U.S., is headed to academia. It was announced yesterday that the renowned immunologist, who became a household name during the Covid-19 pandemic for his role in communicating the value of vaccines, masking, and other basic precautions to the public, will become a professor at Georgetown University in Washington, D.C., starting next month.

"I ask myself, now, at this stage in my life, what do I have to offer to society?" Fauci told Georgetown in a Q&A. "I could do more experiments in the lab and have my lab going, but given what I've been through, I think what I have to offer is experience and inspiration to the younger generation of students."


CMS

Opinion: CMS policy is hampering the 'food as medicine' movement

A growing chorus of nutrition advocates and organizations is pressing insurers, researchers, and the government to value healthy eating as a key part of any effort to stem the rise of chronic conditions. But recent CMS guidelines prevent states from enrolling Medicaid members in food-as-medicine programs for more than six months. That rule threatens to undermine the agency's ambitions to reduce rates of chronic disease by 2030, warns Adam Shyevitch, chief program officer of About Fresh, a Boston-based nonprofit, in a First Opinion for STAT. 

Shyevitch writes that the "food as medicine" movement is in part fighting against deep inequities. That's because chronic poverty can push families to prioritize cheap and filling calories over nutritious meals, leading to a higher risk of chronic conditions, which already affect 60% of Americans. Read more.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Shareholders elect director's romantic partner to Biogen's board, STAT
  • Severe period pain is often dismissed in teens. Many have endometriosis, Washington Post
  • A son died, his parents tried to sue. How U.S. courts protect Big Pharma, Reuters
  • U.K. agency declines to recommend Eli Lilly's Mounjaro for type 2 diabetes, STAT
  • Inside the secretive world of penile enlargement, ProPublica

Thanks for reading, more tomorrow! — Jonathan

Jonathan Wosen is STAT's West Coast biotech & life sciences reporter, based in San Diego.


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments